These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Changes of the endometrium during oral hormonal contraception with ethinyl estradiol sulfonate and norethisterone acetate or d-noregestrel].
    Author: Büttner HH, Göretzlehner G, Rudolf K.
    Journal: Zentralbl Gynakol; 1976; 98(15):914-8. PubMed ID: 970000.
    Abstract:
    48 fertile women took in three weeks 1 mg ethinylestradiolsulfonate weekly and in the 4th week 10 mg norethisterone acetate, respectively d-norgestrel in different dosages (0,5 mgs, 1,0 mgs, 1,5 mgs or 3,0 mgs). On this 48 women 69 abrasiones were made between the first and 37th treatment cycles in order to estimate the endometrium. Ethinylestradiolsulfonate caused for the most part a proliferation of endometrium, which reached to a glandulare cystic hyperplastic endometrium. We did not observe a reduction of the endometrial respond to this depot-estrogen in dependence on the time of taking. Norethisterone acetate and d-norgestrel effected on a different proliferated endometrium a secretory transfer mation always. 48 women, aged 17-41, were treated with weekly dosages of 1 mg ethinylestradiolsulfonate (EES) and a 10 mg dosage of norethisterone acetate (NEA) or a .5 mg.-3.0 mg. dosage of d-norgestrel(d-N) every 4 weeks. 69 abrasions of the endometrium were taken from these patients between the 1st-37th treatment cycles. The EES caused a hyperpasia of the endometrium, increasing with the length of use. The patients given the NEA and d-N developed retronuclear basal secretory vacuoles and an overabundance of glycogen in the abrasion material, which was not dependent on the dosage of the gestagen which was given.
    [Abstract] [Full Text] [Related] [New Search]